Pancreatic Cancer Research

ResearcherShizuoka Cancer CenterActive in the last 2 years

Akihiro Ohba

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9153-3798; OpenAlex author ID A5045539264. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
107
Papers, trials and grants by year

2021: 1 paper · 2022: 3 papers · 2023: 8 papers · 2024: none · 2025: 7 papers

Papers 19

  1. Electronic Patient-Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second-Line Chemotherapy: A Multicenter Observational … First author DOI 10.1002/cam4.71161↗
  2. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  3. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  4. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2025.105826↗
  5. Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407. Co-author DOI 10.1016/j.pan.2025.02.005↗
  6. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  7. Third-line S-1 or FOLFOX treatment in advanced pancreatic cancer who received gemcitabine+nab-paclitaxel and nanoliposomal-irinotecan+5-fluorouracil/leucovorin First author DOI 10.21203/rs.3.rs-5801148/v1↗
  8. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  9. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan P… Co-author DOI 10.1007/s00535-023-01988-7↗
  10. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  11. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  12. Clinical features of germline BRCA1/2 or ATM pathogenic variant positive pancreatic cancer in Japan. Co-author DOI 10.1016/j.pan.2023.10.017↗
  13. Efficient and accurate KRAS genotyping using digital PCR combined with melting curve analysis for ctDNA from pancreatic cancer patients. Co-author DOI 10.1038/s41598-023-30131-y↗
  14. Fine-needle biopsy with 19G needle is effective in combination with endoscopic ultrasound-guided tissue acquisition for genomic profiling of unresectable pancr… Co-author DOI 10.1111/den.14423↗
  15. Clinical course of anorexia-cachexia according to type of first-line chemotherapy for advanced pancreatic cancer Co-author DOI 10.21203/rs.3.rs-3048794/v1↗
  16. Proportion of unresectable pancreatic cancer specimens obtained by endoscopic ultrasound-guided tissue acquisition meeting the OncoGuide™ NCC Oncopanel System … Co-author DOI 10.1007/s00535-022-01926-z↗
  17. The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10147-022-02186-w↗
  18. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-es… Co-author DOI 10.1016/j.ejca.2022.06.010↗
  19. A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s10147-021-02001-y↗

Closest collaborators

The 25 strongest of 107 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chigusa Morizane · 11 shared papers, 2021–2025 · strength 1.72
  2. Takuji Okusaka · 10 shared papers, 2021–2025 · strength 1.55
  3. Masafumi Ikeda · 8 shared papers, 2021–2025 · strength 1.28
  4. Makoto Ueno · 7 shared papers, 2021–2025 · strength 1.14
  5. Junji Furuse · 6 shared papers, 2022–2025 · strength 0.99
  6. Susumu Hijioka · 6 shared papers, 2022–2025 · strength 0.95
  7. Naohiro Okano · 5 shared papers, 2022–2025 · strength 0.79
  8. Hiroshi Imaoka · 5 shared papers, 2022–2025 · strength 0.76
  9. Satoshi Kobayashi · 5 shared papers, 2021–2025 · strength 0.75
  10. Takeshi Terashima · 4 shared papers, 2023–2025 · strength 0.67
  11. Masato Ozaka · 4 shared papers, 2022–2025 · strength 0.66
  12. Hideki Ueno · 4 shared papers, 2022–2023 · strength 0.54
  13. Kohei Nakachi · 3 shared papers, 2023–2025 · strength 0.45
  14. Mitsuhito Sasaki · 3 shared papers, 2021–2023 · strength 0.42
  15. Hidetoshi Kitamura · 3 shared papers, 2022–2023 · strength 0.41
  16. Go Ikeda · 3 shared papers, 2022–2023 · strength 0.41
  17. Tomoyuki Satake · 2 shared papers, 2022–2023 · strength 0.34
  18. Akinori Asagi · 2 shared papers, 2025 · strength 0.32
  19. Yohei Kitano · 2 shared papers, 2025 · strength 0.32
  20. Nana Kimura · 2 shared papers, 2025 · strength 0.32
  21. Kunihiro Tsuji · 2 shared papers, 2025 · strength 0.32
  22. Kumiko Umemoto · 2 shared papers, 2025 · strength 0.32
  23. Masayuki Ueno · 2 shared papers, 2025 · strength 0.32
  24. Rei Suzuki · 2 shared papers, 2025 · strength 0.32
  25. Toshifumi Doi · 2 shared papers, 2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.